Clinuvel Pharmaceuticals Limited (CUVL)

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne that develops therapies for genetic, metabolic and skin disorders, with a focus on photomedicine. Its American depositary shares represent ordinary shares listed in Australia.

The company's main product is SCENESSE (afamelanotide), an implant that stimulates melanin production in the skin. It is approved in Europe, the United States and other markets to increase tolerance to light in adults with erythropoietic protoporphyria, a rare genetic disorder that causes severe pain on exposure to light. Clinuvel is studying afamelanotide in other conditions such as vitiligo and is developing related melanocortin-based compounds, along with consumer photoprotection products.